FDA grants new designation to an INMB pipeline program by end of 2027
Resolves: The FDA grants Fast Track, Breakthrough Therapy, or Orphan Drug designation to an Inmune Bio pipeline candidate.
sec_filing· Regulatory
FDA grants new designation to an INMB pipeline program by end of 2027
Market overview
Derived from Inmune Bio, Inc. (INMB) (CIK 0001711754) 8-K filing analysis
Regulatory prediction market
- Implied probability (Yes)
- 45%
- Closes
- 2027-12-31
About this prediction
Resolution criteria
The FDA grants Fast Track, Breakthrough Therapy, or Orphan Drug designation to an Inmune Bio pipeline candidate.
More Regulatory markets
- Crypto billionaire Harborne faces FCA scrutiny over £5m gift — 55% Yes
- Crypto billionaire Harborne will face FCA scrutiny — 60% Yes
- Crypto billionaire Christopher Harborne’s donation triggers FCA inquiry into funding transparency — 70% Yes
- Crypto billionaire Christopher Harborne will face parliamentary scrutiny over £5m gift — 55% Yes
- Harborne crypto holdings face regulatory scrutiny — 60% Yes
- SEC approves at least 2 new Bitcoin ETFs by Q4 2027 — 75% Yes
- SEC approves Kalshi's crypto futures products by 2026-Q3 — 55% Yes
- Iran's central bank bans crypto mining by 2027 Q1 — 85% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…